leisure time -WSS

leisure time

author：explore 2025-10-04 11:35:42 - browse：1282

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Stanford president to resign after investigation of research

WSS

Resistance to cancer drugs: A new genetic explanation

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

Ebola public health emergency is over, WHO declares

Stanford president to resign after investigation of research

'Reaching a detente': STAT's Helen Branswell on covering Covid

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

leisure time

leisure time

hotspot

New air purifier tech could be key to improving indoor air quality

Celebrate National Dole Whip Day for 3 days this week at Disney

23andMe had bad news about my health. I wish a person had delivered it

Stanford updates investigation of president’s past research

Drug repurposing or repositioning? The language matters

Stanford updates investigation of president’s past research

Hepatitis C has a cure — but many Americans still lack access to it

Food makers tried to stack nutrition panel with preferred experts

Walensky prepares to leave CDC — and Congress — behind

Trump got a 'target letter.' What is one and what does it mean?

focus

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Pig kidney works a record two months in donated body

Plane’s emergency slide plummets from sky, hits Chicago home

How medical schools plan to diversify without affirmative action

FDA approves updated Covid vaccines

Pig kidney works a record two months in donated body

hotspot

hotspot

explore

entertainment